These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33581182)

  • 1. Sacubitril-valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction.
    Passino C; Sciarrone P; Vergaro G; Borrelli C; Spiesshoefer J; Gentile F; Emdin M; Giannoni A
    Int J Cardiol; 2021 May; 330():112-119. PubMed ID: 33581182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sacubitril-valsartan on central and obstructive apneas in heart failure patients with reduced ejection fraction.
    Wang Y; Branco RF; Salanitro M; Penzel T; Schöbel C
    Sleep Breath; 2023 Mar; 27(1):283-289. PubMed ID: 35486312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of discontinuation of sacubitril-valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction.
    Amin OA; Alaarag AF
    Anatol J Cardiol; 2021 Mar; 25(3):163-169. PubMed ID: 33690130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sleep Outcomes From AWAKE-HF: A Randomized Clinical Trial of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
    Owens RL; Birkeland K; Heywood JT; Steinhubl SR; Dorn J; Grant D; Fombu E; Khandwalla R
    J Card Fail; 2021 Dec; 27(12):1466-1471. PubMed ID: 34428592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction.
    Chen F; Tian G; Bai X; Li J; Yuan Z
    Ann Palliat Med; 2021 Aug; 10(8):8684-8691. PubMed ID: 34488357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
    Chin KL; Zomer E; Wang BH; Liew D
    Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacubitril-valsartan initiation in chronic heart failure patients impacts sleep apnea: the ENTRESTO-SAS study.
    Jaffuel D; Nogue E; Berdague P; Galinier M; Fournier P; Dupuis M; Georger F; Cadars MP; Ricci JE; Plouvier N; Picard F; Puel V; Mallet JP; Suehs CM; Molinari N; Bourdin A; Roubille F
    ESC Heart Fail; 2021 Aug; 8(4):2513-2526. PubMed ID: 34102018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
    Khan MS; Felker GM; Piña IL; Camacho A; Bapat D; Ibrahim NE; Maisel AS; Prescott MF; Ward JH; Solomon SD; Januzzi JL; Butler J
    JACC Heart Fail; 2021 Feb; 9(2):137-145. PubMed ID: 33309581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease.
    Raphael DM; Liu Z; Jin Z; Cui X; Han D; He W; Shangguan J; Shen D
    Curr Med Res Opin; 2021 Jul; 37(7):1071-1078. PubMed ID: 33764230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
    Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
    Pascual-Figal D; Wachter R; Senni M; Bao W; Noè A; Schwende H; Butylin D; Prescott MF;
    JACC Heart Fail; 2020 Oct; 8(10):822-833. PubMed ID: 32800508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
    Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
    Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
    N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration.
    Mapelli M; Mattavelli I; Paolillo S; Salvioni E; Magrì D; Galotta A; De Martino F; Mantegazza V; Vignati C; Esposito I; Dell'Aversana S; Paolillo R; Capovilla T; Tamborini G; Nepitella AA; Filardi PP; Agostoni P
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1173-1184. PubMed ID: 37368004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
    Ganesananthan S; Shah N; Shah P; Elsayed H; Phillips J; Parkes A; Morgan A; Yousef Z
    Open Heart; 2020 Oct; 7(2):. PubMed ID: 33020255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Usefulness of Myocardial Work in Patients With Heart Failure and Reduced Ejection Fraction Treated by Sacubitril/Valsartan.
    Bouali Y; Donal E; Gallard A; Laurin C; Hubert A; Bidaut A; Leclercq C; Galli E
    Am J Cardiol; 2020 Jun; 125(12):1856-1862. PubMed ID: 32305222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early improvement of strain imaging parameters predicts long-term response to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: An observational prospective study.
    Camilli M; Iannaccone G; Russo M; Meucci MC; Chiorazzo G; Natali R; Mango F; Bonanni A; Montone RA; Graziani F; Locorotondo G; Massetti M; Lanza GA; Aspromonte N; Crea F; Lombardo A
    Int J Cardiol; 2023 Sep; 387():131110. PubMed ID: 37290664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use and Out-of-Pocket Cost of Sacubitril-Valsartan in Patients With Heart Failure.
    Shore S; Basu T; Kamdar N; Brady P; Birati E; Hummel SL; Chopra V; Nallamothu BK
    J Am Heart Assoc; 2022 Sep; 11(17):e023950. PubMed ID: 36000415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study.
    Acquaro M; Scelsi L; Pasotti B; Seganti A; Spolverini M; Greco A; Schirinzi S; Turco A; Sanzo A; Savastano S; Rordorf R; Ghio S
    Vascul Pharmacol; 2023 Oct; 152():107196. PubMed ID: 37467909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.